Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Outi Vaarala is active.

Publication


Featured researches published by Outi Vaarala.


Cell Host & Microbe | 2015

The Dynamics of the Human Infant Gut Microbiome in Development and in Progression toward Type 1 Diabetes

Aleksandar D. Kostic; Dirk Gevers; Heli Siljander; Tommi Vatanen; Tuulia Hyötyläinen; Anu-Maaria Hämäläinen; Aleksandr Peet; Vallo Tillmann; Päivi Pöhö; Ismo Mattila; Harri Lähdesmäki; Eric A. Franzosa; Outi Vaarala; Marcus C. de Goffau; Hermie J. M. Harmsen; Jorma Ilonen; Suvi Virtanen; Clary B. Clish; Matej Orešič; Curtis Huttenhower; Mikael Knip; Ramnik J. Xavier

Colonization of the fetal and infant gut microbiome results in dynamic changes in diversity, which can impact disease susceptibility. To examine the relationship between human gut microbiome dynamics throughout infancy and type 1 diabetes (T1D), we examined a cohort of 33 infants genetically predisposed to T1D. Modeling trajectories of microbial abundances through infancy revealed a subset of microbial relationships shared across most subjects. Although strain composition of a given species was highly variable between individuals, it was stable within individuals throughout infancy. Metabolic composition and metabolic pathway abundance remained constant across time. A marked drop in alpha-diversity was observed in T1D progressors in the time window between seroconversion and T1D diagnosis, accompanied by spikes in inflammation-favoring organisms, gene functions, and serum and stool metabolites. This work identifies trends in the development of the human infant gut microbiome along with specific alterations that precede T1D onset and distinguish T1D progressors from nonprogressors.


Science Translational Medicine | 2015

Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2.

Syed Sohail Ahmed; Wayne Volkmuth; José S. Duca; Lorenzo Corti; Michele Pallaoro; Alfredo Pezzicoli; Anette Karle; Fabio Rigat; Rino Rappuoli; Vas Narasimhan; Ilkka Julkunen; Arja Vuorela; Outi Vaarala; Hanna Nohynek; Franco Laghi Pasini; Emanuele Montomoli; Claudia Maria Trombetta; Christopher M. Adams; Jonathan B. Rothbard; Lawrence Steinman

Similarity between influenza nucleoprotein and hypocretin receptor 2 may trigger vaccine-associated narcolepsy. Immunological mistaken identity New reports of narcolepsy increased after the vaccination campaign against the 2009 A(H1N1) influenza pandemic in some countries but not others. Now Ahmed et al. examine differences between the vaccines used and find a potential mechanistic explanation for the vaccine-specific effect. They found a peptide in influenza nucleopeptide A that shared protein residues with human hypocretin receptor 2, which has been linked to narcolepsy. The vaccine used in unaffected countries contained less influenza nucleoprotein. Indeed, patients with putative vaccine-associated narcolepsy produced antibodies that cross-reacted to both the influenza and the hypocretin receptor 2 epitopes. Although these data do not demonstrate causation, they provide a possible explanation for the association of this particular influenza vaccination with increased reports of narcolepsy. The sleep disorder narcolepsy is linked to the HLA-DQB1*0602 haplotype and dysregulation of the hypocretin ligand-hypocretin receptor pathway. Narcolepsy was associated with Pandemrix vaccination (an adjuvanted, influenza pandemic vaccine) and also with infection by influenza virus during the 2009 A(H1N1) influenza pandemic. In contrast, very few cases were reported after Focetria vaccination (a differently manufactured adjuvanted influenza pandemic vaccine). We hypothesized that differences between these vaccines (which are derived from inactivated influenza viral proteins) explain the association of narcolepsy with Pandemrix-vaccinated subjects. A mimic peptide was identified from a surface-exposed region of influenza nucleoprotein A that shared protein residues in common with a fragment of the first extracellular domain of hypocretin receptor 2. A significant proportion of sera from HLA-DQB1*0602 haplotype–positive narcoleptic Finnish patients with a history of Pandemrix vaccination (vaccine-associated narcolepsy) contained antibodies to hypocretin receptor 2 compared to sera from nonnarcoleptic individuals with either 2009 A(H1N1) pandemic influenza infection or history of Focetria vaccination. Antibodies from vaccine-associated narcolepsy sera cross-reacted with both influenza nucleoprotein and hypocretin receptor 2, which was demonstrated by competitive binding using 21-mer peptide (containing the identified nucleoprotein mimic) and 55-mer recombinant peptide (first extracellular domain of hypocretin receptor 2) on cell lines expressing human hypocretin receptor 2. Mass spectrometry indicated that relative to Pandemrix, Focetria contained 72.7% less influenza nucleoprotein. In accord, no durable antibody responses to nucleoprotein were detected in sera from Focetria-vaccinated nonnarcoleptic subjects. Thus, differences in vaccine nucleoprotein content and respective immune response may explain the narcolepsy association with Pandemrix.


Current Diabetes Reports | 2013

Human Intestinal Microbiota and Type 1 Diabetes

Outi Vaarala

The role of intestinal microbiota in immune-mediated diseases, such as type 1 diabetes, has deservedly received a lot of attention. Evidently, changes in the intestinal microbiota are associated with type 1 diabetes as demonstrated by recent studies. Children with beta-cell autoimmunity have shown low abundance of butyrate-producing bacteria and increase in the abundance of members of the Bacteroidetes phylum in fecal microbiota. These alterations could explain increased gut permeability, subclinical small intestinal inflammation, and dysregulation of oral tolerance in type 1 diabetes. However, these studies do not provide evidence of the causative role of the gut microbiota in the development of beta-cell autoimmunity, yet. In animal models, the composition of gut microbiota modulates the function of both innate and adaptive immunity, and intestinal bacteria are regulators of autoimmune diabetes. Thus, prevention of type 1 diabetes could, in the future, be based on the interventions targeted to the gut microbiota.


Journal of Immunology | 2015

Th1/Th17 Plasticity Is a Marker of Advanced β Cell Autoimmunity and Impaired Glucose Tolerance in Humans

Linnea Reinert-Hartwall; Jarno Honkanen; Harri M. Salo; Janne K. Nieminen; Kristiina Luopajärvi; Taina Härkönen; Riitta Veijola; Olli Simell; Jorma Ilonen; Aleksandr Peet; Vallo Tillmann; Mikael Knip; Outi Vaarala; Katriina Koski; Matti Koski; Samppa J. Ryhänen; Anu-Maaria Hämäläinen; Anne Ormisson; Valentina Ulich; Elena Kuzmicheva; Sergei Mokurov; Svetlana Markova; Svetlana Pylova; Marina Isakova; Elena Shakurova; Vladimir Petrov; Natalya V. Dorshakova; Tatyana Karapetyan; Tatyana Varlamova; Minna Kiviniemi

Upregulation of IL-17 immunity and detrimental effects of IL-17 on human islets have been implicated in human type 1 diabetes. In animal models, the plasticity of Th1/Th17 cells contributes to the development of autoimmune diabetes. In this study, we demonstrate that the upregulation of the IL-17 pathway and Th1/Th17 plasticity in peripheral blood are markers of advanced β cell autoimmunity and impaired β cell function in human type 1 diabetes. Activated Th17 immunity was observed in the late stage of preclinical diabetes in children with β cell autoimmunity and impaired glucose tolerance, but not in children with early β cell autoimmunity. We found an increased ratio of IFN-γ/IL-17 expression in Th17 cells in children with advanced β cell autoimmunity, which correlated with HbA1c and plasma glucose concentrations in an oral glucose tolerance test, and thus impaired β cell function. Low expression of Helios was seen in Th17 cells, suggesting that Th1/Th17 cells are not converted thymus-derived regulatory T cells. Our results suggest that the development of Th1/Th17 plasticity may serve as a biomarker of disease progression from β cell autoantibody positivity to type 1 diabetes. These data in human type 1 diabetes emphasize the role of Th1/Th17 plasticity as a potential contributor to tissue destruction in autoimmune conditions.


Journal of Crohns & Colitis | 2015

Altered Fecal Microbiota in Paediatric Inflammatory Bowel Disease

Johanna Maukonen; Kaija-Leena Kolho; Monika Paasela; Jarno Honkanen; Paula Klemetti; Outi Vaarala; Maria Saarela

BACKGROUND AND AIMSnSeveral factors support the view of inflammatory bowel disease [IBD] origin in the host responsiveness to intestinal bacteria, although no single bacterial species has been shown as a causative agent in the pathogenesis. Our aim was to analyse the fecal microbiota of paediatric IBD patients at different stages of the disease. In addition, the characteristics of immune response to the bacterial isolates showing very low abundance in IBD were studied.nnnMETHODSnFecal samples [1-3 samples/child] were collected from 10 paediatric patients with crohns disease [CD], and 12 with ulcerative colitis [UC] and from 8 healthy children, for polyphasic microbiological analysis (culture, real-time polymerase chain reaction [PCR], and denaturing gradient gel electrophoresis). In addition, in vitro cytokine responses of peripheral blood mononuclear cells to the bacterial isolates, which showed very low abundance in IBD, were studied.nnnRESULTSnAlthough predominant bacterial diversity was higher in IBD, the numbers of Lachnospiraceae and Coriobacteriaceae bacteria were lower in IBD patients as compared with control children [p < 0.05]. In addition, Ruminococcaceae population diversity was lower in IBD [p < 0.05] and correlated negatively with fecal calprotectin levels. Both abundance and diversity of bifidobacterial populations were lower in children with IBD [p < 0.05], and particularly low numbers of certain bifidobacterial isolates were detected. In CD, we found enhanced up-regulation of interleukin-6 transcripts and impaired RAR-related orphan receptor C response to bifidobacteria, whereas decreased interferon-gamma response was observed in both CD and UC.nnnCONCLUSIONnWe demonstrate altered fecal microbiota in paediatric IBD, particularly low numbers and diversity of bifidobacterial populations. Interestingly, immunological response to bifidobacteria differed between paediatric CD patients and control children.


PLOS ONE | 2015

Altered Activation of Innate Immunity Associates with White Matter Volume and Diffusion in First-Episode Psychosis

Teemu Mäntylä; Outi Mantere; Tuukka T. Raij; Tuula Kieseppä; Hanna Laitinen; Jaana Leiviskä; Minna Torniainen; Lauri Tuominen; Outi Vaarala; Jaana Suvisaari

First-episode psychosis (FEP) is associated with inflammatory and brain structural changes, but few studies have investigated whether systemic inflammation associates with brain structural changes in FEP. Thirty-seven FEP patients (median 27 days on antipsychotic medication), and 19 matched controls were recruited. Serum levels of 38 chemokines and cytokines, and cardiovascular risk markers were measured at baseline and 2 months later. We collected T1- and diffusion-weighted MRIs with a 3 T scanner from the patients at baseline. We analyzed the association of psychosis-related inflammatory markers with gray and white matter (WM) volume using voxel-based morphometry and WM diffusion using tract-based spatial statistics with whole-brain and region-of-interest (ROI) analyses. FEP patients had higher CCL22 and lower TGFα, CXCL1, CCL7, IFN-α2 and ApoA-I than controls. CCL22 decreased significantly between baseline and 2 months in patients but was still higher than in controls. The association between inflammatory markers and FEP remained significant after adjusting for age, sex, smoking and BMI. We did not observe a correlation of inflammatory markers with any symptoms or duration of antipsychotic treatment. Baseline CCL22 levels correlated negatively with WM volume and positively with mean diffusivity and radial diffusivity bilaterally in the frontal lobes in ROI analyses. Decreased serum level of ApoA-I was associated with smaller volume of the medial temporal WM. In whole-brain analyses, CCL22 correlated positively with mean diffusivity and radial diffusivity, and CXCL1 associated negatively with fractional anisotropy and positively with mean diffusivity and radial diffusivity in several brain regions. This is the first report to demonstrate an association between circulating chemokine levels and WM in FEP patients. Interestingly, CCL22 has been previously implicated in autoimmune diseases associated with WM pathology. The results suggest that an altered activation of innate immunity may contribute to WM damage in psychotic disorders.


Clinical & Experimental Allergy | 2015

High level of fecal calprotectin at age 2 months as a marker of intestinal inflammation predicts atopic dermatitis and asthma by age 6

L. Orivuori; K. Mustonen; M. de Goffau; S. Hakala; M. Paasela; Caroline Roduit; Jean-Charles Dalphin; Jon Genuneit; Roger Lauener; Josef Riedler; Juliane Weber; E. von Mutius; Juha Pekkanen; Hermie J. M. Harmsen; Outi Vaarala

Gut microbiota and intestinal inflammation regulate the development of immune‐mediated diseases, such as allergies. Fecal calprotectin is a biomarker of intestinal inflammation.


Lancet Neurology | 2014

Does autoreactivity have a role in narcolepsy

Markku Partinen; Birgitte Rahbek Kornum; Giuseppe Plazzi; Poul Jennum; Ilkka Julkunen; Outi Vaarala

we included the hypothesis that type 1 narcolepsy is an autoimmune disease. As part of this discussion, we identifi ed hypocretin as a possible target of an autoimmune attack leading to narcolepsy. At the time of writing, this idea was supported by data from a report by De la Herran-Arita and colleagues,


Indoor Air | 2016

Moisture damage in home associates with systemic inflammation in children

K. Mustonen; Anne M. Karvonen; Pirkka Kirjavainen; Marjut Roponen; Bianca Schaub; Urs Frey; Harald Renz; Petra Ina Pfefferle; Jon Genuneit; Outi Vaarala; Juha Pekkanen

This study investigated the association between confirmed moisture damage in homes and systemic subclinical inflammation in children. Home inspections were performed in homes of 291 children at the age of 6xa0years. Subclinical inflammation at the age of 6xa0years was assessed by measuring the circulating levels of C-reactive protein (CRP) and leukocytes in peripheral blood and fractional exhaled nitric oxide (FeNO). Proinflammatory cytokines interleukin (IL)-1β and IL-6 and tumor necrosis factor (TNF)-α were measured in unstimulated, and in phorbol 12-myristate 13-acetate and ionomycin (PI), lipopolysaccharide (LPS), or peptidoglycan (PPG)-stimulated whole blood. Major moisture damage in the childs main living areas (living room, kitchen, or childs bedroom) and moisture damage with mold in the bathroom were associated with increased levels of CRP and stimulated production of several proinflammatory cytokines. There were no significant associations between moisture damage/visible mold and leukocyte or FeNO values. The results suggest that moisture damage or mold in home may be associated with increased systemic subclinical inflammation and proinflammatory cytokine responsiveness.


JAMA | 2018

Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes: The TRIGR Randomized Clinical Trial

Mikael Knip; Hans K. Åkerblom; Eva Al Taji; Dorothy J. Becker; Jan Bruining; Luis Castaño; Thomas Danne; Carine De Beaufort; Hans-Michael Dosch; John Dupre; William D. Fraser; Neville J. Howard; Jorma Ilonen; Daniel Konrad; Olga Kordonouri; Jeffrey P. Krischer; Margaret L. Lawson; Johnny Ludvigsson; László Madácsy; Jeffrey L. Mahon; Anne Ormisson; Jerry P. Palmer; Paolo Pozzilli; Erkki Savilahti; Manuel Serrano-Ríos; Marco Songini; Shayne Taback; Outi Vaarala; Neil H. White; Suvi M. Virtanen

Importance Early exposure to complex dietary proteins may increase the risk of type 1 diabetes in children with genetic disease susceptibility. There are no intact proteins in extensively hydrolyzed formulas. Objective To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of type 1 diabetes in young children. Design, Setting, and Participants An international double-blind randomized clinical trial of 2159 infants with human leukocyte antigen–conferred disease susceptibility and a first-degree relative with type 1 diabetes recruited from May 2002 to January 2007 in 78 study centers in 15 countries; 1081 were randomized to be weaned to the extensively hydrolyzed casein formula and 1078 to a conventional formula. The follow-up of the participants ended on February 28, 2017. Interventions The participants received either a casein hydrolysate or a conventional adapted cow’s milk formula supplemented with 20% of the casein hydrolysate. The minimum duration of study formula exposure was 60 days by 6 to 8 months of age. Main Outcomes and Measures Primary outcome was type 1 diabetes diagnosed according to World Health Organization criteria. Secondary outcomes included age at diabetes diagnosis and safety (adverse events). Results Among 2159 newborn infants (1021 female [47.3%]) who were randomized, 1744 (80.8%) completed the trial. The participants were observed for a median of 11.5 years (quartile [Q] 1-Q3, 10.2-12.8). The absolute risk of type 1 diabetes was 8.4% among those randomized to the casein hydrolysate (nu2009=u200991) vs 7.6% among those randomized to the conventional formula (nu2009=u200982) (difference, 0.8% [95% CI, −1.6% to 3.2%]). The hazard ratio for type 1 diabetes adjusted for human leukocyte antigen risk group, duration of breastfeeding, duration of study formula consumption, sex, and region while treating study center as a random effect was 1.1 (95% CI, 0.8 to 1.5; Pu2009=u2009.46). The median age at diagnosis of type 1 diabetes was similar in the 2 groups (6.0 years [Q1-Q3, 3.1-8.9] vs 5.8 years [Q1-Q3, 2.6-9.1]; difference, 0.2 years [95% CI, −0.9 to 1.2]). Upper respiratory infections were the most common adverse event reported (frequency, 0.48 events/year in the hydrolysate group and 0.50 events/year in the control group). Conclusions and Relevance Among infants at risk for type 1 diabetes, weaning to a hydrolyzed formula compared with a conventional formula did not reduce the cumulative incidence of type 1 diabetes after median follow-up for 11.5 years. These findings do not support a need to revise the dietary recommendations for infants at risk for type 1 diabetes. Trial Registration clinicaltrials.gov Identifier: NCT00179777

Collaboration


Dive into the Outi Vaarala's collaboration.

Top Co-Authors

Avatar

Jorma Ilonen

Turku University Hospital

View shared research outputs
Top Co-Authors

Avatar

Mikael Knip

University of Helsinki

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jarno Honkanen

National Institute for Health and Welfare

View shared research outputs
Top Co-Authors

Avatar

Juha Pekkanen

National Institute for Health and Welfare

View shared research outputs
Researchain Logo
Decentralizing Knowledge